Tuesday , October 26 2021

Glenmark gains on getting nod from Russian Ministry of Healthcare for Momate Rhino nasal spray

Mumbai : Glenmark Pharmaceuticals is currently trading at Rs. 640.70, up by 5.40 points or 0.85% from its previous closing of Rs. 635.30 on the BSE. The scrip opened at Rs. 638.10 and has touched a high and low of Rs. 645.40 and Rs. 636.75 respectively. So far 955 shares were traded on the counter.

The BSE group ‘A’ stock of face value Rs. 1 has touched a 52 week high of Rs. 711.55 on 10-Sep-2018 and a 52 week low of Rs. 483.60 on 30-May-2018. Last one week high and low of the scrip stood at Rs. 645.40 and Rs. 615.90 respectively. The current market cap of the company is Rs. 17926.14 crore. The promoters holding in the company stood at 46.54%, while Institutions and Non-Institutions held 39.55% and 13.90% respectively.

Glenmark Pharmaceuticals has received approval from the Ministry of Healthcare, Russia to market Momate Rhino (Mometasone Furoate 50 mcg) metered nasal spray as an over‐the‐counter (OTC) product for the treatment of seasonal and perennial allergic rhinitis in patients above 18 years of age.

Glenmark Pharmaceuticals is a global pharmaceutical company. The company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Its segments are India, United States, Latin America, Europe and Rest of the World (ROW).

Please share this news
<div id="taboola-below-article-thumbnails"></div>
<script type="text/javascript">
  window._taboola = window._taboola || [];
    mode: 'thumbnails-a',
    container: 'taboola-below-article-thumbnails',
    placement: 'Below Article Thumbnails',
    target_type: 'mix'